COVID-19 GenOMICC-GENOMICS ENGLAND PARTNERSHIP

数以千计的冠状病毒重病患者将接受基因密码研究，以帮助科学家了解一个人的基因是否会影响他们对病毒的易感性。NHS将进行一项新的重大人类全基因组测序研究，涉及目前或以前在重症监护病房感染冠状病毒的多达20,000人，以及15,000名有轻度或中度症状的人。基因组学英国公司正在与GenOMICC财团、Illumina和NHS合作发起这项研究活动，这项研究将覆盖英国170个重症监护病房的患者。该项目得到了英国基因组学公司、英国研究与创新公司、卫生与社会保健部和国家卫生研究所的支持。Illumina将对全部35,000个基因组进行测序，并通过实物捐助分担部分成本。这项研究由爱丁堡大学和多家NHS医院推动，将探索冠状病毒对患者的各种影响，通过识别风险最高的患者来支持治疗方法的搜索，并帮助将新疗法快速进入临床试验。

Thousands of patients severely ill with coronavirus will have their genetic code studied to help scientists understand whether a person’s genetics may influence their susceptibility to the virus. A major new human whole genome sequencing study will take place across the NHS, involving up to 20,000 people currently or previously in an intensive care unit with coronavirus, as well as 15,000 individuals who have mild or moderate symptoms. Genomics England, is partnering with the GenOMICC consortium, Illumina and the NHS to launch the research drive, which will reach patients in 170 intensive care units throughout the UK. The project is backed by Genomics England, UK Research and Innovation, the Department of Health and Social Care and the National Institute for Health Research. Illumina will sequence all 35,000 genomes and share some of the cost via an in-kind contribution. The study, facilitated by the University of Edinburgh and multiple NHS hospitals, will explore the varied effects coronavirus has on patients, supporting the search for treatments by identifying those most at risk and helping to fast-track new therapies into clinical trials.